TRIMTECH Therapeutics
Develops small molecule therapies to degrade protein aggregates in neurodegenerative diseases
$47MSeed+
Role not disclosedLoading investors…
Activity from announced rounds
Develops small molecule therapies to degrade protein aggregates in neurodegenerative diseases
Develops AI-driven control software for energy-intensive industries
Develops next-generation cell assay technology for drug discovery
Develops cellulose-based alternative to titanium dioxide for cosmetics, food, and coatings
Develops AI-driven energy management software to optimize energy use in real estate portfolios
Pitching Cambridge Enterprise Ventures? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room